Vertex, CRISPR prep filing for gene-editing blood disorder therapy
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, gene editing, sickle cell disease, Vertex
0 Comment
CRISPR/Cas9
Verve starts trials of cholesterol drug in test of base editing technique
cholesterol, CRISPR/Cas9, gene editing, heterozygous familial hypercholesterolaemia, Leqvio, PCSK9, Praluent, Repatha, Verve Therapeutics
0 Comment
EHA: Vertex, CRISPR build case for gene-editing drug
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, EHA 2022, gene editing, sickle cell disease, Vertex Pharma
0 Comment
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma
0 Comment
Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug
ATTR amyloidosis, CRISPR/Cas9, gene editing, Intellia Therapeutics, rare disease, Regeneron
0 Comment
Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance
CRISPR Therapeutics, CRISPR/Cas9, gene editing, Obsidian Therapeutics, partnering, Vertex Pharma
0 Comment
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disorders
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, gene editing, sickle cell disease, Vertex Pharma
0 Comment
Biogen teams up with gene-editing startup Scribe on ALS programme
amyotrophic lateral sclerosis, Biogen, central nervous system, CRISPR/Cas9, licensing, neurodegenerative disease, Scribe Therapeutics
0 Comment
1 2